No Detail Found!

Effect of metformin on P53 and its interacting partners in breast cancer cell line MCFf-7

Author(s)
Mehroze Amin School of Biological Sciences, University of the Punjab,Quaid-i-Azam Campus, Lahore 54590,Pakistan
Afifa Yaqub School of Biological Sciences, University of the Punjab,Quaid-i-Azam Campus, Lahore 54590,Pakistan
Qindeel Fatima School of Biological Sciences, University of the Punjab,Quaid-i-Azam Campus, Lahore 54590,Pakistan
Rabail Hassan Toor School of Biological Sciences, University of the Punjab,Quaid-i-Azam Campus, Lahore 54590,Pakistan; UVM Cancer Center, Larner College of Medicine, Department of Biochemistry, University of Vermont,Burlington, VT 05405,USA
Abdul Rauf Shakoori School of Biological Sciences, University of the Punjab,Quaid-i-Azam Campus, Lahore 54590,Pakista; Cancer Research Centre, University of the Punjab,Quaid-i-Azam Campus, Lahore 54590,Pakistan
Abstract
Metformin is known to favor p53 anti-cancer activity and promote apoptosis and cell senescence in cancer cells. It is also known to decrease the incidence of several cancers though it is not entirely true for breast cancer. In the present study, the effect of metformin has been studied on the expression of p53 and its interacting partners MDM-2, PIRH2 and ?Np73 in breast cancer cell line MCF-7 and non-cancerous kidney cell line HEK2093. Analysis of the cytotoxicity and proliferation parameters showed that higher of metformin were cytotoxic for the breast cancer cells with EC50 of 22.75µM. Analysis of expression of p53 and the interacting partner genes showed that metformin upregulated p53 expression in a dose-dependent manner, while the expression of interacting partners is downregulated indicating that metformin exhibits the anti-cancerous effect by regulating the p53 pathway. Altogether this study reports the effect of metformin on the expression of p53 and its interacting partners MDM2, PIRH2 and ?Np73in breast cancer cell line MCF-7, thereby providing evidence that metformin modulates p53 pathway to exhibit its anti-cancer property. Hence , metformin can be a potential therapeutic candidate for breast cancer treatment. However, further investigations are required to provide insight into the therapeutic potential od metformin for cancer.
Publication Details
Page(s) 2699-2705
Published Journal: Pakistan Journal of Zoology, Volume: 54, Issue: 6, Year: 2022

Request the full text from PASTIC

Keywords
Breast cancer, metformin, p53, Metastasis, NP73, PIRH2, MDM2
0

Citations

0

Downloads

69

Views